跳至主要内容
临床试验/NCT06496841
NCT06496841已完成不适用

A Comparison of Transnasal Versus Ultrasound-guided Suprazygomatic Approaches for Sphenopalatine Ganglion Blocks in Persistent Idiopathic Facial Pain

Diskapi Teaching and Research Hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
1
主要终点
Numerical Rating Scale (NRS)

研究概览

简要总结

The International Headache Society defines persistent idiopathic facial pain (PIFP) as persistent facial pain that does not have the characteristics of cranial neuralgia, is blunt, persistent, persistent, bothersome and not attributable to another disorder. The management of persistent idiopathic facial pain (PIFP) is complex. The sphenopalatine ganglion (SPG) has been the target of interventional treatment of many facial pain syndromes. The sphenopalatine ganglion can be accessed by transnasal access and ultrasound or scopy guidance. In this study, datas compared the efficacy of transnasal approach and ultrasound-guided suprazigomatic approach in sphenopalatine ganglion block in patients with persistent idiopathic facial pain.

详细描述

Patients with chronic head and facial pain are frequently referred to us and some of these patients are persistent idiopathic facial pain patients who do not respond to conservative treatment. Various interventional treatment modalities can be applied to these patients. One of the treatments we frequently apply is sphenopalatine ganglion (SPG) blockage, which has an important place in the pathogenesis of chronic headache. The SPG is the target area for the treatment of cluster headache, migraine, postherpetic neuralgia, trigeminal neuralgia and other atypical facial pain syndromes due to its anatomical localisation and its role in the trigemino-cervical reflex. Although there are various techniques for SPG block, the simplest and most easily applicable is the transnasal approach and the traditional method is to apply a block with a cotton-tipped swab. Various local anaesthetics can be used, the most commonly used local anaesthetic is 2-3 ml of 2% or 10% lidocaine, usually administered through one nostril for 30 minutes. It is also possible to access SPG via the suprazygomatic route, and studies have shown that SPG block applied via the suprazygomatic route provides effective treatment of chronic headaches. In ultrasound-guided SPG block, after visualising the pterygopalatine fossa with USG, 3-4 mL of 2% lidocaine is administered to the area and blockage is achieved.

Our study was designed retrospectively. The primary aim of the study was to compare the efficacy of transnasal and suprazigomatic routes based on Numerical Rating Scale (NRS) pain scores by reviewing the files of patients who underwent sphenopalatine ganglion block for persistent idiopathic facial pain. The pain scores recorded before the procedure and one and four weeks after the procedure will be compared.

In this study, primary aim is to evaluate the efficacy of these two treatment modalities, with retrospectively evaluate the Visual Analogue Scale (VAS) score, HIT-6 (Headache Impact Test-6) score and headache diary data of the patients who have previously undergone these treatments in the pain clinic.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of persistent idiopathic facial pain according to ICHD-3 beta criteria
  • Moderate to severe pain (pain of 6 or more on a numeric pain scale of 0-10)
  • Persistence of pain for more than 6 months
  • Pain unresponsive to conservative methods

排除标准

  • Presence of secondary headache (tumor, bleeding, stroke, etc.)
  • Cognitive impairment
  • Hepatic or renal insufficiency
  • Local or systemic infection
  • Coagulopathy
  • Patient refusal to accept treatment

研究组 & 干预措施

Transnasal sphenopalatine ganglion block group

transnasal administration of lidocaine to the sphenopalatine ganglion

干预措施: Transnasal Sphenopalatine ganglion block (Drug)

Ultrasound-guided suprazygomatic sphenopalatine ganglion block group

ultrasound-guided suprazygomatic approach

干预措施: Ultrasound-guided suprazygomatic sphenopalatine ganglion block (Drug)

结局指标

主要结局

Numerical Rating Scale (NRS)

时间窗: Change from baseline to 1st hour, 1st week and 4th weeks after treatment

NRS is a pain screening Scale, in time using a 0-10 Scale, with zero meaning ''no pain'' and 10 meaning ''the worst pain imaginable''.

次要结局

  • HIT-6 (Headache impact test)(Change from baseline to 1st hour, 1st week and 4th weeks after treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Damla Yürük

Principal investigator

Diskapi Teaching and Research Hospital

研究点 (1)

Loading locations...

相似试验